Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leading biopharmaceutical company that specializes in developing cutting-edge RNA interference (RNAi) therapeutics. This revolutionary approach selectively silences disease-causing genes, making it possible to treat a broad range of illnesses, from genetic disorders to infectious diseases and cancer.
Projects that make a difference.
During my time at Alnylam Pharmaceuticals, I had the privilege of working with the LuMac team, which focused on launching a groundbreaking treatment for primary hyperoxaluria type 1 (PH1), a rare kidney stone disease affecting a very small population worldwide. As a valued member of the Global Marketing Department, I provided invaluable assistance in content creation, design, and strategic planning, while analyzing campaign information and creating a tactical plan to drive the drug brand's success.
PH1 Fact Sheet
One of my most significant contributions to the team was designing a PH1 Fact Sheet specially tailored to physicians, nephrologists, and urologists. This comprehensive sheet highlighted critical information about the disease, including its low prevalence, and underwent a rigorous commercial review board process to ensure its accuracy. Additionally, I created logos for internal contests and managed respondent data, collecting over 300 submissions from colleagues worldwide.
Registry Logo
LuMac Team Logo
I also designed the internal logo for the LuMAC team. The Logo plays upon: Teamwork, being the third child, patient population (two Adults, 1 child), brand colors, and the firefly paving the way for Luma consistency. Variations are shown below the final logo.
